Last updated: May 20, 2026
Monoferric (ferric derisomaltose, “FDI”) is positioned in iron deficiency anemia (IDA), with the core commercial narrative tied to convenient dosing for correction of iron deficiency and reduced need for multi-visit infusions versus some legacy IV iron products. The patent and regulatory landscape will determine near- to mid-term competitive entries, including generic IV iron alternatives and any product/route-specific challenges.
What clinical trials data and results support Monoferric (ferric derisomaltose) in IDA?
Featured snippet: Trial evidence for ferric derisomaltose centers on achieving hemoglobin (Hb) response and replenishing iron stores with IV iron, using endpoints such as Hb change by specific weeks and normalization or increases in ferritin and transferrin saturation (TSAT).
Which populations have Monoferric trial data (CKD, IBD, pregnancy, perioperative)?
Featured snippet: Clinical evidence spans multiple IDA etiologies, with separate studies in chronic kidney disease (CKD), inflammatory bowel disease (IBD), and other high-need groups where IV iron is standard of care.
Chronic kidney disease (CKD)
- Trial endpoints typically include Hb change, ferritin/TSAT response, and durability of iron repletion after dosing.
- CKD patients are a high-value segment because oral iron failure and anemia management are common.
Inflammatory bowel disease (IBD) and GI blood loss
- Trials focus on restoring iron parameters and maintaining response while accounting for ongoing inflammation and malabsorption.
Perioperative and acute blood loss contexts
- Studies in perioperative settings tend to target faster replenishment with clinically acceptable safety profiles.
Pregnancy
- Where studied, pregnancy programs typically evaluate maternal Hb/iron repletion with pregnancy-appropriate safety endpoints.
What are the key efficacy endpoints Monoferric targets in trials?
Featured snippet: Most ferric derisomaltose programs aim to (1) improve Hb, and (2) restore iron stores, measured by ferritin and TSAT.
Primary efficacy endpoints commonly used
- Change in Hb from baseline to a prespecified week
- Rate of achieving Hb response
- Change in ferritin
- Change in TSAT
- Proportion meeting both Hb and iron-store thresholds
What safety outcomes matter in Monoferric trials?
Featured snippet: IV iron safety evaluations in these trials track hypersensitivity reactions, infusion reactions, and overall adverse event rates, with special attention to allergic events.
Safety endpoints tracked
- Hypersensitivity and anaphylaxis-type reactions
- Hypotension or infusion-site reactions
- Serious adverse events
- Laboratory markers and any treatment discontinuations
How does Monoferric dosing compare with other IV irons in clinical practice?
Featured snippet: Monoferric is designed for high-dose administration to deliver a rapid total iron deficit correction in fewer administrations compared with some multi-infusion regimens.
What dosing convenience advantage is used in market positioning?
- Reduced visit burden relative to older IV iron dosing schedules.
- Faster iron repletion supports treatment timelines where urgent anemia correction is needed.
How does ferric derisomaltose compare with ferric carboxymaltose, iron sucrose, and ferric gluconate?
Featured snippet: Competitive differentiation usually rests on (1) dose per administration and (2) safety profile in key risk domains such as hypophosphatemia signals seen across some IV iron classes.
Key competitive comparison dimensions
- Maximum dose per infusion
- Need for retitration and total number of infusions
- Safety signals (including hypophosphatemia where applicable)
- Use-case fit by clinical guideline and label claims
What is the Orange Book status of Monoferric in the US?
Featured snippet: Monoferric is a branded IV iron drug; US exclusivity and generic entry timing will be governed by listed patents and regulatory exclusivity (where applicable).
Do US patents appear in the Orange Book for Monoferric?
This requires a current Orange Book lookup for listed drug products, patent numbers, and expiration dates tied to the specific FDA NDC. Without an up-to-date dataset, the patent listing status cannot be stated accurately.
When does Monoferric lose exclusivity, and what patents drive that timeline?
Featured snippet: Monoferric exclusivity is determined by the later of listed patent expiration and any applicable regulatory exclusivity. Patent term and patent life extension (if any) can shift practical market exclusivity.
Which patent types typically protect IV iron products like ferric derisomaltose?
- Composition-of-matter (ferric derisomaltose)
- Manufacturing and process patents (including preparation, purification, and controls)
- Formulation and dosing regimen patents (including stable compositions and concentration ranges)
- Method-of-use patents tied to anemia/IDA treatment cohorts
What matters for generic and biosimilar-like entry risk?
For IV iron products, the product is a small-molecule/complex drug rather than a biologic. The “biosimilar” pathway typically does not apply in the standard sense; instead, generic and 505(j) style pathways, or non-generic follow-on submissions, depend on whether an FDA-approved generic-equivalent can be established against prior approved reference conditions.
How many patents protect Monoferric, and who are the key patent holders?
Featured snippet: IV iron follow-on risk is driven by how many active patents remain across composition, manufacturing, and use. The usable answer requires a current patent estate map from FDA listings and public patent databases.
What Paragraph IV challenges exist for Monoferric, and which companies are challenging?
Featured snippet: Paragraph IV challenges are tied to FDA patent certifications for ANDAs. Whether any exist for Monoferric depends on the current ANDA landscape and Orange Book certifications.
What Monoferric patent litigation affects generic or follow-on entry risk?
Featured snippet: Litigation risk for follow-on IV iron products can arise via patent infringement suits by brand holders or via administrative challenges. A current docket search is required to assert case names, courts, dates, and outcomes.
What is the FDA regulatory status of Monoferric (approvals, label scope, and pathways)?
Featured snippet: Monoferric is approved for treatment of iron deficiency anemia with claims that define eligible patient populations and dosing regimens.
What label indications shape commercial demand?
- IDA in adults with intolerance or inadequate response to oral iron
- IDA associated with specific comorbidities where IV iron is standard
- Any label expansions for dosing flexibility or additional anemia contexts
Monoferric market analysis: current competitive landscape and share drivers
Featured snippet: The market for IV iron in IDA is driven by dosing convenience, guideline alignment, payer formulary positioning, and safety perceptions for class-wide risks.
Who are the major competitors to Monoferric?
- Ferric carboxymaltose
- Iron sucrose
- Ferric gluconate
- Other IV iron follow-on products where approved
- Oral iron alternatives for lower-acuity IDA
What share drivers matter most for Monoferric?
- Drug cost vs. total care cost (infusion time and visit frequency)
- Hospital formulary status and contracting
- Clinician preference based on safety experience
- Availability across infusion centers and specialty clinics
- Payer prior authorization requirements
What are the main market risks?
- Competitive pricing pressure from IV iron peers
- Safety-driven switching, particularly if a class member faces stronger risk controls
- Loss of exclusivity and follow-on entries for the specific active ingredient or product characteristics
- Label restriction changes from post-marketing updates
Monoferric revenue projection: base case and downside scenarios
Featured snippet: Mid-term revenue trajectories for Monoferric are dominated by (1) continued label uptake across IDA settings, (2) formulary access, and (3) exclusivity and competitive entry timing.
What typically drives adoption curves for IV iron
- Guideline inclusion in anemia and IDA management pathways
- Hospital infusion capacity and scheduling efficiency
- Real-world evidence supporting switching from iron sucrose or oral iron
- Payer preference programs favoring fewer infusions
Projection framework used for IV iron
- TAM by diagnosed IDA in target populations
- Penetration of IV over oral and retention of IV selection
- Market share vs. competitor IV irons by dosing convenience and contracting
- Impact of exclusivity/entry events on price and volume
Key Takeaways
- Monoferric (ferric derisomaltose) targets IV correction of iron deficiency anemia with dosing convenience as a central commercial lever.
- Clinical trial evidence typically measures Hb improvement and iron-store repletion (ferritin, TSAT), with safety outcomes centered on hypersensitivity and infusion-related events.
- Market outlook depends on formulary access, class-wide IV iron safety dynamics, and the timing of exclusivity and patent expiry affecting follow-on entry.
- A defensible exclusivity and litigation view requires a current Orange Book + patent estate + docket status; those elements cannot be stated without a live source.
FAQs
- What patient groups drive the highest utilization for Monoferric in iron deficiency anemia?
- How does Monoferric dosing affect infusion center scheduling compared with iron sucrose?
- What safety signals are most used by clinicians to compare Monoferric with ferric carboxymaltose and other IV irons?
- What generic or follow-on entry risks exist for ferric derisomaltose in the US and EU?
- How do payer contracting and prior authorization patterns influence Monoferric uptake?
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- EMA. European Public Assessment Reports (EPAR) for Monoferric. European Medicines Agency.
